GlaxoSmithKline plc Q3 2025 Earnings Recap

GSK's Q3 2025 results reflect robust growth with total sales increasing by 8%, driven by strong performance in specialty medicines, and a significant upgrade in guidance for the year. The company also reported positive cash generation and progress in R&D, highlighting its commitment to innovation and sustainability.

Key Takeaways

• Total sales reached GBP 8.5 billion in Q3, up 8% year-over-year, with specialty medicines growing 16%.
• Core operating profit increased by 11%, and core EPS rose 14% to 55p.
• GSK secured four FDA approvals this year, including for BLENREP, and expects to launch a low-carbon version of Ventolin in 2026.
• Cash generation stood at GBP 6.3 billion year-to-date, supporting ongoing investments and a quarterly dividend of 16p.
• Full-year specialty guidance has been upgraded from low teens to mid-teens percentage growth.